Fate Therapeutics (FATE) Revenue & Revenue Breakdown
Fate Therapeutics Revenue Highlights
Latest Revenue (Y)
$63.53M
Latest Revenue (Q)
$6.77M
Main Segment (Y)
Upfront Fee And Equity Premium
Main Geography (Y)
Upfront Fee And Equity Premium
Fate Therapeutics Revenue by Period
Fate Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $63.53M | -34.03% |
| 2022-12-31 | $96.30M | 72.44% |
| 2021-12-31 | $55.85M | 77.66% |
| 2020-12-31 | $31.43M | 194.33% |
| 2019-12-31 | $10.68M | 125.32% |
| 2018-12-31 | $4.74M | 15.44% |
| 2017-12-31 | $4.11M | -6.72% |
| 2016-12-31 | $4.40M | 81.08% |
| 2015-12-31 | $2.43M | 100.00% |
| 2014-12-31 | - | -100.00% |
| 2013-12-31 | $971.00K | -63.63% |
| 2012-12-31 | $2.67M | 128.21% |
| 2011-12-31 | $1.17M | - |
Fate Therapeutics generated $63.53M in revenue during NA 2023, up -34.03% compared to the previous quarter, and up 1340.36% compared to the same period a year ago.
Fate Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $6.77M | 251.79% |
| 2024-03-31 | $1.93M | 14.86% |
| 2023-12-31 | $1.68M | -13.79% |
| 2023-09-30 | $1.94M | 108.36% |
| 2023-06-30 | $933.00K | -98.42% |
| 2023-03-31 | $58.98M | 32.97% |
| 2022-12-31 | $44.36M | 196.08% |
| 2022-09-30 | $14.98M | -19.24% |
| 2022-06-30 | $18.55M | 0.73% |
| 2022-03-31 | $18.41M | 7.89% |
| 2021-12-31 | $17.07M | 19.98% |
| 2021-09-30 | $14.22M | 6.06% |
| 2021-06-30 | $13.41M | 20.37% |
| 2021-03-31 | $11.14M | -29.91% |
| 2020-12-31 | $15.90M | 110.32% |
| 2020-09-30 | $7.56M | 38.30% |
| 2020-06-30 | $5.46M | 117.30% |
| 2020-03-31 | $2.52M | -10.24% |
| 2019-12-31 | $2.80M | 15.36% |
| 2019-09-30 | $2.43M | -13.77% |
| 2019-06-30 | $2.82M | 7.03% |
| 2019-03-31 | $2.63M | 58.46% |
| 2018-12-31 | $1.66M | 61.89% |
| 2018-09-30 | $1.03M | -0.10% |
| 2018-06-30 | $1.03M | 0.10% |
| 2018-03-31 | $1.03M | -0.10% |
| 2017-12-31 | $1.03M | 0.10% |
| 2017-09-30 | $1.03M | - |
| 2017-06-30 | $1.03M | -0.10% |
| 2017-03-31 | $1.03M | - |
| 2016-12-31 | $1.03M | 0.10% |
| 2016-09-30 | $1.03M | -0.10% |
| 2016-06-30 | $1.03M | -22.31% |
| 2016-03-31 | $1.32M | 22.86% |
| 2015-12-31 | $1.08M | 4.87% |
| 2015-09-30 | $1.03M | 211.85% |
| 2015-06-30 | $329.00K | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | -100.00% |
| 2013-09-30 | $209.00K | -27.93% |
| 2013-06-30 | $290.00K | -38.56% |
| 2013-03-31 | $472.00K | -26.59% |
| 2012-12-31 | $643.00K | 21.78% |
| 2012-09-30 | $528.00K | - |
Fate Therapeutics generated $6.77M in revenue during Q2 2024, up 251.79% compared to the previous quarter, and up 11.48% compared to the same period a year ago.
Fate Therapeutics Revenue Breakdown
Fate Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 20 |
|---|---|---|---|
| Upfront Fee And Equity Premium | $31.20M | $23.10M | $6.50M |
Fate Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Upfront Fee And Equity Premium (100.00%).
Quarterly Revenue by Product
| Product/Service | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Upfront Fee And Equity Premium | - | $31.20M | $31.20M | $31.20M | $6.00M | $4.20M | $6.70M | $6.10M | $4.10M | $3.80M | $1.80M |
Fate Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 22 | Dec 20 |
|---|---|---|
| Upfront Fee And Equity Premium | $23.10M | $6.50M |
Fate Therapeutics's latest annual revenue breakdown by geography, as of Dec 22: Upfront Fee And Equity Premium (100.00%).
Quarterly Revenue by Country
| Country | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|
| Upfront Fee And Equity Premium | $31.20M | $6.00M | $4.20M | $6.70M | $6.10M | $4.10M | $3.80M | $1.80M |
Fate Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 23: Upfront Fee And Equity Premium (100.00%).
Fate Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BEAM | Beam Therapeutics | $377.71M | $11.77M |
| CRSP | CRISPR Therapeutics | $370.00M | $517.00K |
| BPMC | Blueprint Medicines | $249.38M | $138.16M |
| RCUS | Arcus Biosciences | $117.00M | $39.00M |
| FATE | Fate Therapeutics | $63.53M | $6.77M |
| NTLA | Intellia Therapeutics | $36.27M | $6.96M |
| CRBU | Caribou Biosciences | $34.48M | $3.46M |
| RLAY | Relay Therapeutics | $25.55M | - |
| VERV | Verve Therapeutics | $11.76M | $5.70M |
| ATRA | Atara Biotherapeutics | $8.57M | $28.64M |
| IPSC | Century Therapeutics | $2.23M | $771.00K |
| LIFE | aTyr Pharma | $353.00K | $235.00K |
| EDIT | Editas Medicine | - | - |
| PRME | Prime Medicine | - | - |
| SANA | Sana Bio | - | - |
FATE Revenue FAQ
What is Fate Therapeutics’s yearly revenue?
Fate Therapeutics's yearly revenue for 2023 was $63.53M, representing a decrease of -34.03% compared to 2022. The company's yearly revenue for 2022 was $96.3M, representing an increase of 72.44% compared to 2021. FATE's yearly revenue for 2021 was $55.85M, representing an increase of 77.66% compared to 2020.
What is Fate Therapeutics’s quarterly revenue?
Fate Therapeutics's quarterly revenue for Q2 2024 was $6.77M, a 251.79% increase from the previous quarter (Q1 2024), and a 625.83% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $1.92M, a 14.86% increase from the previous quarter (Q4 2023), and a -96.74% decrease year-over-year (Q1 2023). FATE's quarterly revenue for Q4 2023 was $1.68M, a -13.79% decrease from the previous quarter (Q3 2023), and a -96.22% decrease year-over-year (Q4 2022).
What is Fate Therapeutics’s revenue growth rate?
Fate Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 13.76%, and for the last 5 years (2019-2023) was 494.88%.
What are Fate Therapeutics’s revenue streams?
Fate Therapeutics's revenue streams in c 23 are Upfront Fee And Equity Premium
What is Fate Therapeutics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Fate Therapeutics was Upfront Fee And Equity Premium. This segment made a revenue of $31.2M, representing 100.00% of the company's total revenue.